Saturday 17 October 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLC Basic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.
1.20
0.02
−1.64%
Follow BGLC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 485.01 | 206.86 | 206.86 | 206.86 |
Piotroski F-Score |
4 | 3 | 4 | 3 | 5 | 5 | — | — |
P/S ratio |
0.99 | 0.52 | 8.48 | 15.82 | 27.28 | 19.87 | 19.87 | 19.87 |
Altman Z-Score |
6.34 | 2.05 | 29.56 | 49.38 | 93.92 | — | — | — |
Altman Z″-Score (non-manufacturers) |
13.32 | 5.59 | 7.50 | 6.60 | 7.71 | 6.11 | 12.86 | 17.24 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 347.51 | 60,756.12 | 141.55 | 141.55 | 141.55 |
P/Operating CF |
7.63 | 22.76 | (105.90) | 362.74 | 754.73 | 242.71 | 242.71 | 242.71 |
Beneish M-Score |
(3.31) | (1.84) | (3.54) | (2.67) | (1.59) | 78.92 | (2.25) | — |
P/B ratio |
0.85 | 0.60 | 8.58 | 25.94 | 50.77 | 33.97 | 33.97 | 33.97 |
Price to Tangible BV |
0.85 | 0.60 | 8.58 | 25.94 | 50.77 | 33.97 | 33.97 | 33.97 |
EV/Sales |
0.46 | 0.08 | 7.89 | 15.63 | 27.12 | 19.63 | 19.63 | 19.63 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 311.34 | 162.54 | 162.54 | 162.54 |
EV/Operating CF |
(1.85) | (0.34) | (42.28) | 309.61 | 39,394.09 | 404.51 | 404.51 | 404.51 |
EV/FCF |
(1.81) | (0.31) | (39.08) | 343.33 | 60,404.27 | 139.83 | 139.83 | 139.83 |
Quick Ratio |
9.00 | 3.10 | 4.24 | 2.52 | 2.39 | 2.02 | 16.96 | 20.40 |
Current Ratio |
10.46 | 3.81 | 4.93 | 3.00 | 3.07 | 2.37 | 17.10 | 20.64 |
Net Debt/EBITDA |
1.49 | 3.44 | 2.45 | 11.40 | (1.81) | (2.00) | 3.66 | (11.91) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.13% | 0.35% | 3.66% | 3.81% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.04 |
Asset Turnover |
0.75 | 0.87 | 0.97 | 1.19 | 1.36 | 2.01 | 0.09 | 0.00 |
Operating CF/Net income |
0.62 | 1.31 | 0.69 | (1.55) | 0.01 | 0.51 | 0.88 | (10.34) |
Capex/Depreciation |
(0.22) | (1.48) | (1.38) | (0.51) | (0.03) | 10.30 | (0.24) | (0.98) |
| (35.24%) | (17.78%) | (32.21%) | (5.14%) | 10.86% | 28.11% | (18.64%) | 0.00% | |
| (30.32%) | (14.64%) | (26.11%) | (3.89%) | 7.63% | 19.29% | (17.10%) | 0.00% | |
ROIC |
(40.51%) | (24.93%) | (43.47%) | (4.00%) | 13.02% | 20.36% | (55.87%) | 11.53% |
Return on Tangible Assets |
(45.73%) | (22.83%) | (33.16%) | (6.44%) | 11.64% | 17.10% | (21.55%) | 1.68% |
Average Days of Receivables |
31.90 | 63.88 | 36.60 | 97.70 | 93.87 | 128.87 | 45.70 | 39.20 |
Research and Development Expense of Revenue |
0.68% | 0.50% | 0.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
54.77% | 42.11% | 31.11% | 15.83% | 9.56% | 11.70% | 280.79% | 113.94% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10.70% | 1.48% | 5.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.66 | 1.07 | 0.08 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 7.73 | 14.94 | 0.00 | 1.72 |
Earnings Yield |
(40.43%) | (32.49%) | (3.17%) | (0.04%) | 0.21% | 0.48% | 0.48% | 0.48% |
Free Cash Flow Yield |
(25.57%) | (46.51%) | (2.38%) | 0.29% | 0.00% | 0.71% | 0.71% | 0.71% |
Revenue per Share |
4.00 | 5.34 | 0.62 | 7.58 | 9.37 | 13.29 | 0.18 | 0.38 |
Operating CF per Share |
(0.99) | (1.17) | (0.11) | 0.38 | 0.01 | 0.64 | (0.30) | (0.50) |
Capex per Share |
(0.02) | (0.13) | (0.01) | (0.04) | 0.00 | 1.22 | (0.02) | (0.07) |
Free Cash Flow per Share |
(1.01) | (1.30) | (0.12) | 0.35 | 0.00 | 1.87 | (0.32) | (0.57) |
Cash per Share |
2.18 | 2.46 | 0.37 | 1.47 | 1.49 | 3.25 | 1.19 | 2.28 |
Shareholders Equity per Share |
4.64 | 4.67 | 0.61 | 4.63 | 5.03 | 7.77 | 1.56 | 2.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.64 | 4.67 | 0.61 | 4.63 | 5.03 | 7.77 | 1.56 | 2.75 |
Free Cash Flow |
(1.88) | (2.32) | (1.97) | 0.50 | 0.01 | 1.60 | (0.23) | (0.31) |
Working Capital |
4.93 | 5.48 | 6.42 | 4.02 | 4.82 | 4.61 | 0.83 | 1.24 |
Capital Expenditures |
(0.04) | (0.23) | (0.15) | (0.05) | 0.00 | 1.05 | (0.01) | (0.04) |
Net Current Asset Value |
4.81 | 5.32 | 6.30 | 3.95 | 4.76 | 4.53 | 0.77 | 1.17 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 343.27 | 175.52 | 175.52 | 175.52 |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.01 | 0.00 | (0.09) | 0.10 | 0.19 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 345.27 | 177.68 | 177.68 | 177.68 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.11 | 0.10 | 0.07 | 0.07 | 0.07 | 0.06 | 0.17 | 0.12 |
Cash ROIC |
(14.82%) | (18.27%) | (12.65%) | 5.66% | 0.06% | 16.86% | (11.35%) | (11.03%) |
Accounts Receivable Turnover |
6.42 | 7.19 | 5.00 | 3.44 | 3.58 | 5.64 | 6.56 | 0.00 |
Accounts Payable Turnover |
8.42 | 5.66 | 5.17 | 4.99 | 4.28 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
6.14 | 6.51 | 7.98 | 7.74 | 8.22 | 16.34 | 6.21 | 0.00 |
Average Days of Payables |
0.13 | 66.74 | 60.63 | 70.25 | 66.20 | 119.67 | 0.00 | 0.00 |
Days of Inventory on Hand |
38.96 | 61.65 | 49.20 | 36.91 | 50.06 | 44.39 | 39.02 | 30.42 |
Average Receivables |
1.16 | 1.32 | 1.95 | 3.18 | 3.73 | 2.02 | 0.02 | — |
Average Payables |
0.75 | 1.45 | 1.63 | 1.94 | 2.59 | — | — | — |
Average Inventory |
1.03 | 1.26 | 1.06 | 1.25 | 1.35 | 0.59 | 0.01 | — |
Average Assets |
9.84 | 10.92 | 10.07 | 9.16 | 9.84 | 5.67 | 1.44 | — |
Average Common Equity |
8.47 | 8.99 | 8.16 | 6.92 | 6.92 | 3.89 | 1.32 | — |
Columns are period end dates